| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Candidiasis, Oral | 1 | 2021 | 58 | 0.87 | Why? |
| Splenic Infarction | 1 | 2020 | 67 | 0.81 | Why? |
| Coronary Occlusion | 1 | 2020 | 138 | 0.74 | Why? |
| Mesenteric Ischemia | 1 | 2020 | 128 | 0.73 | Why? |
| Carotid Intima-Media Thickness | 1 | 2017 | 179 | 0.64 | Why? |
| Vasoconstriction | 1 | 2017 | 153 | 0.62 | Why? |
| Reverse Transcriptase Inhibitors | 2 | 2018 | 309 | 0.62 | Why? |
| Glucosylceramidase | 2 | 2019 | 11 | 0.56 | Why? |
| HIV Infections | 12 | 2020 | 11620 | 0.55 | Why? |
| Shoulder Dislocation | 2 | 2018 | 18 | 0.55 | Why? |
| Cerebrovascular Circulation | 1 | 2017 | 340 | 0.55 | Why? |
| Down Syndrome | 1 | 2017 | 397 | 0.49 | Why? |
| Drug Resistance, Viral | 4 | 2018 | 1083 | 0.49 | Why? |
| HIV-1 | 6 | 2018 | 3365 | 0.48 | Why? |
| Ischemia | 1 | 2020 | 901 | 0.47 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2018 | 952 | 0.47 | Why? |
| Joint Instability | 2 | 2018 | 20 | 0.42 | Why? |
| HIV Protease Inhibitors | 2 | 2018 | 434 | 0.42 | Why? |
| Substantia Nigra | 1 | 2019 | 22 | 0.40 | Why? |
| Cucurbitaceae | 1 | 2018 | 3 | 0.39 | Why? |
| Genes, Recessive | 1 | 2018 | 35 | 0.38 | Why? |
| Elastic Tissue | 1 | 2018 | 14 | 0.38 | Why? |
| Hereditary Central Nervous System Demyelinating Diseases | 1 | 2018 | 3 | 0.38 | Why? |
| Phosphoric Monoester Hydrolases | 1 | 2018 | 37 | 0.38 | Why? |
| Bursitis | 1 | 2018 | 25 | 0.38 | Why? |
| Anti-HIV Agents | 4 | 2018 | 2209 | 0.37 | Why? |
| Founder Effect | 1 | 2018 | 92 | 0.36 | Why? |
| Gaucher Disease | 1 | 2019 | 63 | 0.36 | Why? |
| Dideoxynucleosides | 1 | 2018 | 92 | 0.35 | Why? |
| Animal Feed | 1 | 2018 | 72 | 0.35 | Why? |
| Thromboembolism | 1 | 2021 | 2101 | 0.35 | Why? |
| Homeodomain Proteins | 1 | 2018 | 93 | 0.35 | Why? |
| Superoxide Dismutase | 1 | 2018 | 155 | 0.35 | Why? |
| Apolipoprotein A-I | 1 | 2018 | 148 | 0.34 | Why? |
| Professional Role | 1 | 2017 | 1280 | 0.34 | Why? |
| Sus scrofa | 1 | 2018 | 205 | 0.34 | Why? |
| Hypercholesterolemia | 1 | 2018 | 175 | 0.32 | Why? |
| HIV Integrase Inhibitors | 1 | 2018 | 173 | 0.32 | Why? |
| Pharmacists | 1 | 2017 | 1246 | 0.31 | Why? |
| Fabry Disease | 1 | 2017 | 106 | 0.30 | Why? |
| Nucleosides | 1 | 2017 | 221 | 0.28 | Why? |
| Neurodevelopmental Disorders | 1 | 2018 | 284 | 0.26 | Why? |
| HIV Fusion Inhibitors | 1 | 2004 | 80 | 0.26 | Why? |
| Self Report | 1 | 2015 | 3802 | 0.25 | Why? |
| Genotype | 7 | 2018 | 4697 | 0.25 | Why? |
| HIV Envelope Protein gp41 | 1 | 2004 | 153 | 0.25 | Why? |
| Patient Care Team | 1 | 2017 | 3556 | 0.24 | Why? |
| Latent Tuberculosis | 1 | 2016 | 324 | 0.24 | Why? |
| Disease Management | 2 | 2017 | 6841 | 0.24 | Why? |
| Polymorphism, Genetic | 2 | 2018 | 1074 | 0.23 | Why? |
| Myalgia | 1 | 2017 | 1015 | 0.21 | Why? |
| Blood Coagulation Factor Inhibitors | 1 | 2020 | 41 | 0.21 | Why? |
| Microsatellite Repeats | 2 | 2001 | 99 | 0.20 | Why? |
| Glucose Tolerance Test | 1 | 2011 | 238 | 0.20 | Why? |
| Glucose Intolerance | 1 | 2011 | 115 | 0.20 | Why? |
| Extremities | 1 | 2020 | 179 | 0.19 | Why? |
| Genetic Predisposition to Disease | 5 | 2018 | 4027 | 0.19 | Why? |
| Seizures | 1 | 2018 | 1163 | 0.19 | Why? |
| Ataxia Telangiectasia | 1 | 2018 | 12 | 0.19 | Why? |
| Orotic Acid | 1 | 1998 | 2 | 0.19 | Why? |
| Blood Coagulation Factors | 1 | 2020 | 223 | 0.18 | Why? |
| Fagus | 1 | 2017 | 1 | 0.18 | Why? |
| Breath Holding | 1 | 2017 | 13 | 0.18 | Why? |
| Carbon Sequestration | 1 | 2017 | 5 | 0.18 | Why? |
| Betamethasone | 1 | 2018 | 63 | 0.18 | Why? |
| Hyperaldosteronism | 1 | 2017 | 17 | 0.18 | Why? |
| Antioxidants | 1 | 2018 | 1593 | 0.18 | Why? |
| Phenylephrine | 1 | 2017 | 20 | 0.18 | Why? |
| Braces | 1 | 2017 | 14 | 0.18 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.18 | Why? |
| Compliance | 1 | 2017 | 28 | 0.18 | Why? |
| Cumulative Trauma Disorders | 1 | 2017 | 27 | 0.17 | Why? |
| Bacterial Proteins | 1 | 2016 | 1318 | 0.17 | Why? |
| Rotator Cuff Injuries | 1 | 2017 | 32 | 0.17 | Why? |
| HLA-DR4 Antigen | 1 | 1996 | 5 | 0.17 | Why? |
| Aorta | 1 | 2020 | 355 | 0.17 | Why? |
| Mycobacterium tuberculosis | 1 | 2016 | 1164 | 0.17 | Why? |
| Immobilization | 1 | 2017 | 74 | 0.17 | Why? |
| Heart Failure | 2 | 2017 | 6638 | 0.17 | Why? |
| Genetic Linkage | 1 | 1996 | 87 | 0.16 | Why? |
| Stroke | 1 | 2020 | 8839 | 0.16 | Why? |
| Pharmacogenomic Testing | 1 | 2017 | 115 | 0.16 | Why? |
| Ultrasonography, Doppler, Transcranial | 1 | 2017 | 143 | 0.16 | Why? |
| Forests | 1 | 2017 | 132 | 0.16 | Why? |
| Aphasia, Primary Progressive | 1 | 2015 | 8 | 0.16 | Why? |
| Viral Load | 3 | 2020 | 15850 | 0.16 | Why? |
| Norepinephrine | 1 | 2017 | 152 | 0.16 | Why? |
| Aldosterone | 1 | 2017 | 155 | 0.16 | Why? |
| Parkinson Disease | 1 | 2019 | 1414 | 0.16 | Why? |
| Basal Ganglia Diseases | 1 | 2015 | 16 | 0.16 | Why? |
| Tuberculosis, Pulmonary | 1 | 2016 | 1171 | 0.15 | Why? |
| Membrane Proteins | 1 | 2016 | 1733 | 0.15 | Why? |
| Headache | 1 | 2017 | 2257 | 0.15 | Why? |
| Neoplastic Syndromes, Hereditary | 1 | 2005 | 14 | 0.15 | Why? |
| Adrenal Cortex Hormones | 2 | 2020 | 6537 | 0.15 | Why? |
| Italy | 9 | 2020 | 38444 | 0.15 | Why? |
| Frontotemporal Dementia | 1 | 2015 | 55 | 0.15 | Why? |
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1996 | 203 | 0.14 | Why? |
| Male | 50 | 2020 | 367725 | 0.14 | Why? |
| Female | 49 | 2021 | 380317 | 0.14 | Why? |
| Hepacivirus | 2 | 2017 | 1509 | 0.14 | Why? |
| Arteries | 1 | 2017 | 283 | 0.14 | Why? |
| Central Nervous System | 1 | 2020 | 701 | 0.14 | Why? |
| Genetics, Medical | 1 | 2005 | 64 | 0.14 | Why? |
| Amputation | 1 | 2017 | 331 | 0.14 | Why? |
| Darunavir | 1 | 2018 | 477 | 0.14 | Why? |
| Acinetobacter Infections | 1 | 2017 | 273 | 0.13 | Why? |
| Societies, Scientific | 1 | 2017 | 414 | 0.13 | Why? |
| Burns | 2 | 2018 | 466 | 0.13 | Why? |
| Humans | 74 | 2021 | 930598 | 0.13 | Why? |
| Acinetobacter baumannii | 1 | 2017 | 378 | 0.13 | Why? |
| Hypotension | 1 | 2017 | 392 | 0.13 | Why? |
| Mental Health Services | 1 | 2021 | 3007 | 0.13 | Why? |
| Facility Regulation and Control | 1 | 2003 | 22 | 0.13 | Why? |
| Peptide Fragments | 1 | 2004 | 2075 | 0.13 | Why? |
| Soccer | 1 | 2017 | 259 | 0.12 | Why? |
| Acquired Immunodeficiency Syndrome | 2 | 2017 | 533 | 0.12 | Why? |
| Vasoconstrictor Agents | 1 | 2017 | 714 | 0.12 | Why? |
| Adult | 36 | 2020 | 244371 | 0.12 | Why? |
| Middle Aged | 32 | 2020 | 270681 | 0.12 | Why? |
| Pedigree | 2 | 2018 | 502 | 0.12 | Why? |
| Anesthesia, General | 1 | 2017 | 470 | 0.12 | Why? |
| Fluorouracil | 1 | 2012 | 169 | 0.11 | Why? |
| Surgery Department, Hospital | 1 | 2021 | 954 | 0.11 | Why? |
| Liver Cirrhosis, Biliary | 1 | 2001 | 42 | 0.11 | Why? |
| Depression | 1 | 2015 | 14116 | 0.11 | Why? |
| Tissue Banks | 1 | 2001 | 66 | 0.11 | Why? |
| Endosonography | 1 | 2002 | 150 | 0.11 | Why? |
| Standard of Care | 1 | 2017 | 1297 | 0.10 | Why? |
| Encephalopathy, Bovine Spongiform | 1 | 1999 | 7 | 0.10 | Why? |
| Digestive System Neoplasms | 1 | 2002 | 146 | 0.10 | Why? |
| Psychosine | 1 | 2019 | 2 | 0.10 | Why? |
| Immunocompromised Host | 1 | 2016 | 5150 | 0.10 | Why? |
| HIV Seropositivity | 2 | 2018 | 320 | 0.10 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2020 | 1671 | 0.10 | Why? |
| Colorectal Neoplasms | 2 | 2012 | 1884 | 0.10 | Why? |
| Creutzfeldt-Jakob Syndrome | 1 | 1999 | 35 | 0.10 | Why? |
| Bioethical Issues | 1 | 2003 | 233 | 0.10 | Why? |
| Ethics, Research | 1 | 2003 | 328 | 0.09 | Why? |
| Splenorenal Shunt, Surgical | 2 | 1996 | 3 | 0.09 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 1115 | 0.09 | Why? |
| Carcinoma, Hepatocellular | 2 | 2001 | 1222 | 0.09 | Why? |
| Linkage Disequilibrium | 2 | 2001 | 191 | 0.09 | Why? |
| Arthroscopy | 1 | 2018 | 46 | 0.09 | Why? |
| Prodromal Symptoms | 1 | 2019 | 133 | 0.09 | Why? |
| Genetic Heterogeneity | 1 | 2018 | 77 | 0.09 | Why? |
| Shoulder | 1 | 2018 | 96 | 0.09 | Why? |
| Shoulder Joint | 1 | 2018 | 57 | 0.09 | Why? |
| Hospitals, University | 1 | 2021 | 4173 | 0.09 | Why? |
| Adenocarcinoma | 1 | 2005 | 651 | 0.09 | Why? |
| Treatment Outcome | 11 | 2020 | 51732 | 0.09 | Why? |
| Hepatitis C, Chronic | 1 | 2017 | 973 | 0.09 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2012 | 1573 | 0.09 | Why? |
| Inflammation | 2 | 2018 | 13255 | 0.09 | Why? |
| Endoscopy, Digestive System | 1 | 2002 | 352 | 0.09 | Why? |
| Cross-Sectional Studies | 6 | 2021 | 53120 | 0.09 | Why? |
| Homozygote | 1 | 2018 | 230 | 0.08 | Why? |
| Portasystemic Shunt, Surgical | 1 | 1996 | 6 | 0.08 | Why? |
| Aged | 25 | 2021 | 215776 | 0.08 | Why? |
| Exome | 1 | 2018 | 207 | 0.08 | Why? |
| Enzyme Replacement Therapy | 1 | 2017 | 65 | 0.08 | Why? |
| Diagnosis, Differential | 5 | 2017 | 7220 | 0.08 | Why? |
| Liver Neoplasms | 2 | 2001 | 1666 | 0.08 | Why? |
| Child, Preschool | 6 | 2021 | 36283 | 0.08 | Why? |
| Gastrointestinal Transit | 1 | 1995 | 8 | 0.08 | Why? |
| HIV Antigens | 1 | 2016 | 102 | 0.08 | Why? |
| Depressive Disorder, Major | 1 | 2015 | 852 | 0.08 | Why? |
| Phenotype | 3 | 2018 | 4037 | 0.08 | Why? |
| Whole Exome Sequencing | 1 | 2018 | 437 | 0.08 | Why? |
| Arousal | 1 | 1995 | 53 | 0.08 | Why? |
| Sleep, REM | 1 | 1995 | 46 | 0.07 | Why? |
| Portacaval Shunt, Surgical | 1 | 1994 | 3 | 0.07 | Why? |
| Drug Monitoring | 2 | 2018 | 1408 | 0.07 | Why? |
| Recurrence | 3 | 2018 | 3675 | 0.07 | Why? |
| Cholelithiasis | 1 | 1995 | 47 | 0.07 | Why? |
| Mycobacterium Infections | 1 | 2005 | 72 | 0.07 | Why? |
| Biological Specimen Banks | 1 | 2003 | 1142 | 0.07 | Why? |
| Receptors, Angiotensin | 1 | 1995 | 53 | 0.07 | Why? |
| Genetic Association Studies | 1 | 2018 | 559 | 0.07 | Why? |
| Varicose Veins | 1 | 1994 | 30 | 0.07 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.07 | Why? |
| Ascites | 1 | 1994 | 65 | 0.07 | Why? |
| Seasons | 1 | 2017 | 4071 | 0.07 | Why? |
| Glucocorticoids | 2 | 2018 | 4431 | 0.07 | Why? |
| Mutation | 4 | 2019 | 12376 | 0.07 | Why? |
| White Matter | 1 | 2018 | 369 | 0.07 | Why? |
| France | 2 | 2020 | 12074 | 0.07 | Why? |
| Ethics, Medical | 1 | 2001 | 533 | 0.07 | Why? |
| Skin Diseases, Bacterial | 1 | 2005 | 105 | 0.07 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2018 | 669 | 0.07 | Why? |
| Forecasting | 2 | 2017 | 4492 | 0.07 | Why? |
| Lymphocyte Activation | 2 | 2016 | 2742 | 0.07 | Why? |
| Lipopolysaccharides | 1 | 2018 | 848 | 0.06 | Why? |
| Liver Cirrhosis | 2 | 1996 | 1810 | 0.06 | Why? |
| Prospective Studies | 8 | 2018 | 43301 | 0.06 | Why? |
| Child | 8 | 2021 | 70012 | 0.06 | Why? |
| Coinfection | 2 | 2020 | 6820 | 0.06 | Why? |
| Tertiary Care Centers | 1 | 2021 | 8248 | 0.06 | Why? |
| Ritonavir | 1 | 2018 | 4212 | 0.06 | Why? |
| Prevalence | 7 | 2018 | 25773 | 0.06 | Why? |
| Methotrexate | 1 | 2017 | 471 | 0.06 | Why? |
| Elective Surgical Procedures | 1 | 2021 | 5338 | 0.06 | Why? |
| Immunoglobulin Gm Allotypes | 1 | 1991 | 2 | 0.06 | Why? |
| Lymphoma, AIDS-Related | 1 | 2001 | 13 | 0.06 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.06 | Why? |
| Electroencephalography | 2 | 1999 | 1242 | 0.06 | Why? |
| Tandem Mass Spectrometry | 1 | 2018 | 1031 | 0.06 | Why? |
| DNA, Complementary | 1 | 2004 | 568 | 0.06 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 1996 | 1969 | 0.06 | Why? |
| Drug Utilization | 1 | 2017 | 619 | 0.06 | Why? |
| Milk Proteins | 2 | 1989 | 47 | 0.06 | Why? |
| Time Factors | 5 | 2020 | 31397 | 0.06 | Why? |
| Emergency Medical Services | 1 | 2018 | 3557 | 0.06 | Why? |
| HLA-DQ Antigens | 1 | 1991 | 48 | 0.06 | Why? |
| Pancreatic Neoplasms | 1 | 1998 | 609 | 0.06 | Why? |
| HLA-DR Antigens | 2 | 1991 | 563 | 0.05 | Why? |
| Age Factors | 3 | 2020 | 21039 | 0.05 | Why? |
| Pneumonia, Pneumocystis | 2 | 1996 | 322 | 0.05 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.05 | Why? |
| Ischemic Attack, Transient | 1 | 1995 | 439 | 0.05 | Why? |
| Factor V | 1 | 2020 | 52 | 0.05 | Why? |
| Alzheimer Disease | 2 | 1996 | 1020 | 0.05 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.05 | Why? |
| Selection, Genetic | 1 | 2004 | 691 | 0.05 | Why? |
| Protein S | 1 | 2020 | 150 | 0.05 | Why? |
| Postoperative Complications | 2 | 2017 | 5861 | 0.05 | Why? |
| Lymphoma, Non-Hodgkin | 2 | 2001 | 403 | 0.05 | Why? |
| Reference Values | 2 | 1998 | 795 | 0.05 | Why? |
| Protein C | 1 | 2020 | 141 | 0.05 | Why? |
| Disease Outbreaks | 3 | 2021 | 27595 | 0.05 | Why? |
| Myocardium | 2 | 1998 | 2323 | 0.05 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2011 | 6166 | 0.05 | Why? |
| Swine | 1 | 2018 | 3352 | 0.05 | Why? |
| Cross Infection | 2 | 2021 | 8675 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| Longitudinal Studies | 2 | 2019 | 9893 | 0.05 | Why? |
| Dementia | 2 | 1999 | 1861 | 0.05 | Why? |
| Food Hypersensitivity | 2 | 1989 | 397 | 0.05 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.05 | Why? |
| Factor VIII | 1 | 2020 | 229 | 0.05 | Why? |
| Swine Diseases | 1 | 2018 | 1219 | 0.05 | Why? |
| Hamartoma | 2 | 2005 | 21 | 0.04 | Why? |
| Radioimmunoassay | 1 | 2017 | 25 | 0.04 | Why? |
| Accidents, Occupational | 1 | 2018 | 46 | 0.04 | Why? |
| Molecular Sequence Data | 1 | 2004 | 3198 | 0.04 | Why? |
| Biomarkers | 4 | 2019 | 23361 | 0.04 | Why? |
| Aging | 3 | 1996 | 3581 | 0.04 | Why? |
| Chlorophyll | 1 | 2017 | 34 | 0.04 | Why? |
| Skin Transplantation | 1 | 2018 | 50 | 0.04 | Why? |
| Cells, Cultured | 2 | 2016 | 5835 | 0.04 | Why? |
| Paracrine Communication | 1 | 1998 | 73 | 0.04 | Why? |
| Bone Marrow Transplantation | 1 | 2001 | 343 | 0.04 | Why? |
| Langerhans Cells | 1 | 1987 | 14 | 0.04 | Why? |
| HIV Reverse Transcriptase | 1 | 2017 | 104 | 0.04 | Why? |
| Centromere | 1 | 1996 | 12 | 0.04 | Why? |
| Carotenoids | 1 | 2017 | 70 | 0.04 | Why? |
| Saudi Arabia | 1 | 2018 | 4423 | 0.04 | Why? |
| HIV Protease | 1 | 2017 | 86 | 0.04 | Why? |
| Europe | 4 | 2017 | 12702 | 0.04 | Why? |
| Cardiomyopathy, Dilated | 1 | 2000 | 251 | 0.04 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.04 | Why? |
| Recombination, Genetic | 1 | 2004 | 1265 | 0.04 | Why? |
| Myocardial Contraction | 1 | 1998 | 123 | 0.04 | Why? |
| Amino Acid Substitution | 1 | 2004 | 1706 | 0.04 | Why? |
| Mediterranean Region | 1 | 2017 | 276 | 0.04 | Why? |
| Cerebrovascular Disorders | 1 | 1995 | 1040 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2017 | 264 | 0.04 | Why? |
| Interferon-gamma | 1 | 2016 | 2711 | 0.04 | Why? |
| Plant Leaves | 1 | 2017 | 233 | 0.04 | Why? |
| Dapsone | 1 | 1996 | 59 | 0.04 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.04 | Why? |
| Genes, APC | 1 | 2005 | 2 | 0.04 | Why? |
| Jurkat Cells | 1 | 1996 | 273 | 0.04 | Why? |
| Supranuclear Palsy, Progressive | 1 | 2015 | 20 | 0.04 | Why? |
| Disease-Free Survival | 2 | 2017 | 1654 | 0.04 | Why? |
| Cardiac Output | 1 | 2017 | 183 | 0.04 | Why? |
| Adenomatous Polyposis Coli | 1 | 2005 | 11 | 0.04 | Why? |
| Tunisia | 1 | 1998 | 543 | 0.04 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2018 | 10649 | 0.04 | Why? |
| Monitoring, Intraoperative | 1 | 2017 | 140 | 0.04 | Why? |
| Ultrasonography | 2 | 2019 | 4409 | 0.04 | Why? |
| Pneumocystis | 1 | 1995 | 9 | 0.04 | Why? |
| Dietary Supplements | 1 | 2018 | 2251 | 0.04 | Why? |
| CD4 Lymphocyte Count | 1 | 2011 | 1517 | 0.04 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1996 | 170 | 0.04 | Why? |
| Diet | 1 | 2018 | 2052 | 0.04 | Why? |
| Apolipoproteins E | 1 | 1996 | 170 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2004 | 12361 | 0.04 | Why? |
| Arterial Pressure | 1 | 2017 | 208 | 0.04 | Why? |
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2005 | 41 | 0.04 | Why? |
| Hospitals, Urban | 1 | 2021 | 950 | 0.04 | Why? |
| Epidemiological Monitoring | 1 | 2018 | 3493 | 0.04 | Why? |
| Adolescent | 7 | 2018 | 86841 | 0.04 | Why? |
| Insulin Resistance | 1 | 2011 | 669 | 0.04 | Why? |
| DNA Repair | 1 | 2005 | 114 | 0.04 | Why? |
| Burn Units | 1 | 2017 | 179 | 0.04 | Why? |
| Sequence Analysis, DNA | 1 | 2004 | 2830 | 0.04 | Why? |
| Microbial Sensitivity Tests | 1 | 2004 | 2886 | 0.04 | Why? |
| Athletic Injuries | 1 | 2017 | 208 | 0.04 | Why? |
| Telomere | 1 | 1996 | 146 | 0.04 | Why? |
| HLA Antigens | 1 | 2001 | 830 | 0.04 | Why? |
| Risk Factors | 6 | 2018 | 71621 | 0.03 | Why? |
| Fibrinogen | 1 | 2020 | 1048 | 0.03 | Why? |
| Risk | 1 | 2016 | 5288 | 0.03 | Why? |
| Genetic Research | 1 | 2003 | 6 | 0.03 | Why? |
| Vascular Stiffness | 1 | 2017 | 264 | 0.03 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 1996 | 260 | 0.03 | Why? |
| Colonic Polyps | 1 | 2005 | 117 | 0.03 | Why? |
| Chlamydia Infections | 1 | 1996 | 248 | 0.03 | Why? |
| Anti-Infective Agents | 2 | 2004 | 1766 | 0.03 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 1316 | 0.03 | Why? |
| Paris | 1 | 2017 | 1287 | 0.03 | Why? |
| Stress, Physiological | 1 | 2017 | 378 | 0.03 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.03 | Why? |
| DNA Mutational Analysis | 1 | 2005 | 581 | 0.03 | Why? |
| Infant | 4 | 2018 | 30274 | 0.03 | Why? |
| Genetic Counseling | 1 | 2005 | 229 | 0.03 | Why? |
| Organoplatinum Compounds | 1 | 2012 | 76 | 0.03 | Why? |
| Leucovorin | 1 | 2012 | 70 | 0.03 | Why? |
| Waiting Lists | 1 | 2021 | 1388 | 0.03 | Why? |
| Amino Acid Sequence | 1 | 2004 | 6049 | 0.03 | Why? |
| Milk | 2 | 1989 | 158 | 0.03 | Why? |
| Luminescent Measurements | 1 | 2017 | 924 | 0.03 | Why? |
| Spatio-Temporal Analysis | 1 | 2018 | 1182 | 0.03 | Why? |
| Hemorrhage | 1 | 1994 | 3013 | 0.03 | Why? |
| Human Genome Project | 1 | 2001 | 20 | 0.03 | Why? |
| Creatinine | 1 | 1998 | 1443 | 0.03 | Why? |
| Biomarkers, Pharmacological | 1 | 2012 | 150 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2016 | 17020 | 0.03 | Why? |
| Pharmacogenetics | 1 | 2012 | 222 | 0.03 | Why? |
| Anesthesiology | 1 | 2021 | 1163 | 0.03 | Why? |
| HIV | 1 | 2017 | 1116 | 0.03 | Why? |
| Young Adult | 4 | 2018 | 93724 | 0.03 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.03 | Why? |
| Immunoglobulin E | 2 | 1989 | 557 | 0.03 | Why? |
| Decision Trees | 1 | 2002 | 441 | 0.03 | Why? |
| Pregnancy | 2 | 2021 | 23879 | 0.02 | Why? |
| Operating Rooms | 1 | 2021 | 1841 | 0.02 | Why? |
| Leukoplakia, Oral | 1 | 1989 | 21 | 0.02 | Why? |
| Sex Characteristics | 1 | 1998 | 1120 | 0.02 | Why? |
| SARS Virus | 1 | 2003 | 13021 | 0.02 | Why? |
| Aged, 80 and over | 6 | 2019 | 88759 | 0.02 | Why? |
| Genotyping Techniques | 1 | 2012 | 360 | 0.02 | Why? |
| Genetic Engineering | 1 | 2001 | 325 | 0.02 | Why? |
| Survival Analysis | 2 | 2017 | 7592 | 0.02 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2012 | 801 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Ataxia | 1 | 1999 | 133 | 0.02 | Why? |
| Uterine Cervical Neoplasms | 1 | 1987 | 842 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Cohort Studies | 3 | 2018 | 36005 | 0.02 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.02 | Why? |
| Bayes Theorem | 1 | 2017 | 3237 | 0.02 | Why? |
| Sheep | 1 | 1999 | 420 | 0.02 | Why? |
| Myoclonus | 1 | 1999 | 133 | 0.02 | Why? |
| Viruses | 1 | 1991 | 2238 | 0.02 | Why? |
| Personnel, Hospital | 1 | 2021 | 2273 | 0.02 | Why? |
| Cognition | 1 | 1996 | 1394 | 0.02 | Why? |
| Body Mass Index | 1 | 2020 | 4306 | 0.02 | Why? |
| Cattle | 2 | 1999 | 1336 | 0.02 | Why? |
| Tissue and Organ Procurement | 1 | 2018 | 1277 | 0.02 | Why? |
| Stroke Volume | 1 | 2017 | 2153 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Sclerotherapy | 1 | 1996 | 23 | 0.02 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.02 | Why? |
| Iatrogenic Disease | 1 | 1999 | 304 | 0.02 | Why? |
| Equipment Design | 1 | 2017 | 3095 | 0.02 | Why? |
| Radioligand Assay | 1 | 1995 | 7 | 0.02 | Why? |
| Incidence | 3 | 2017 | 25622 | 0.02 | Why? |
| Sarcolemma | 1 | 1995 | 17 | 0.02 | Why? |
| Prognosis | 2 | 2016 | 32490 | 0.02 | Why? |
| Sleep Stages | 1 | 1995 | 52 | 0.02 | Why? |
| Cecum | 1 | 1995 | 63 | 0.02 | Why? |
| Microscopy, Electron | 2 | 2004 | 830 | 0.02 | Why? |
| Radioallergosorbent Test | 2 | 1989 | 4 | 0.02 | Why? |
| Polymerase Chain Reaction | 2 | 1995 | 6740 | 0.02 | Why? |
| Radiography | 1 | 2003 | 1576 | 0.02 | Why? |
| Multiple Sclerosis | 1 | 1991 | 2600 | 0.02 | Why? |
| Hong Kong | 1 | 2004 | 3361 | 0.02 | Why? |
| Hepatorenal Syndrome | 1 | 1994 | 26 | 0.02 | Why? |
| Pneumonia | 2 | 2003 | 5652 | 0.02 | Why? |
| Genome-Wide Association Study | 1 | 2012 | 1648 | 0.02 | Why? |
| Esophageal and Gastric Varices | 1 | 1996 | 117 | 0.02 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.02 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.02 | Why? |
| Cell Division | 1 | 2004 | 136 | 0.02 | Why? |
| Molecular Dynamics Simulation | 1 | 2017 | 4155 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Hepatic Encephalopathy | 1 | 1994 | 88 | 0.02 | Why? |
| Skin Ulcer | 1 | 2005 | 98 | 0.02 | Why? |
| Animals | 4 | 2018 | 78931 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2021 | 5883 | 0.02 | Why? |
| Community-Acquired Infections | 1 | 1996 | 2328 | 0.02 | Why? |
| Electronic Health Records | 1 | 2017 | 3492 | 0.02 | Why? |
| Cholecystectomy | 1 | 1995 | 198 | 0.02 | Why? |
| Disease Susceptibility | 1 | 1996 | 4002 | 0.02 | Why? |
| Methylprednisolone | 1 | 2004 | 2107 | 0.02 | Why? |
| Nervous System | 1 | 1995 | 303 | 0.02 | Why? |
| Virus Replication | 1 | 2004 | 14331 | 0.02 | Why? |
| Abscess | 1 | 2005 | 234 | 0.02 | Why? |
| Spain | 1 | 2021 | 15545 | 0.01 | Why? |
| Peritonitis | 1 | 1994 | 217 | 0.01 | Why? |
| Venous Thromboembolism | 1 | 2020 | 4273 | 0.01 | Why? |
| Probability | 1 | 1996 | 923 | 0.01 | Why? |
| Physician's Role | 1 | 2001 | 853 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 1998 | 25144 | 0.01 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 1261 | 0.01 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Cell Nucleus | 1 | 2004 | 399 | 0.01 | Why? |
| Neoplasm Staging | 1 | 1998 | 1999 | 0.01 | Why? |
| Genetic Carrier Screening | 1 | 2000 | 18 | 0.01 | Why? |
| Etoposide | 1 | 2001 | 115 | 0.01 | Why? |
| Lactose Intolerance | 1 | 1989 | 9 | 0.01 | Why? |
| Sepsis | 1 | 1998 | 3517 | 0.01 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.01 | Why? |
| Lactoglobulins | 1 | 1989 | 31 | 0.01 | Why? |
| Caseins | 1 | 1989 | 32 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2018 | 48226 | 0.01 | Why? |
| Mouth | 1 | 1995 | 622 | 0.01 | Why? |
| Wakefulness | 1 | 1995 | 598 | 0.01 | Why? |
| Immune Tolerance | 1 | 2005 | 608 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Cyclophosphamide | 1 | 2001 | 387 | 0.01 | Why? |
| Doxorubicin | 1 | 2001 | 313 | 0.01 | Why? |
| Pulmonary Alveoli | 1 | 2004 | 867 | 0.01 | Why? |
| Down-Regulation | 1 | 1995 | 1416 | 0.01 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.01 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2012 | 3607 | 0.01 | Why? |
| Public Policy | 1 | 2001 | 1894 | 0.01 | Why? |
| Research | 1 | 2001 | 2115 | 0.01 | Why? |
| Algorithms | 1 | 2005 | 7346 | 0.01 | Why? |
| Infant, Newborn | 2 | 1998 | 23105 | 0.01 | Why? |
| Antibodies, Neoplasm | 1 | 1987 | 15 | 0.01 | Why? |
| Multicenter Studies as Topic | 1 | 1995 | 2437 | 0.01 | Why? |
| International Cooperation | 1 | 2001 | 3436 | 0.01 | Why? |
| Infusions, Intravenous | 1 | 2001 | 1224 | 0.01 | Why? |
| Condylomata Acuminata | 1 | 1987 | 62 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Carcinoma in Situ | 1 | 1987 | 58 | 0.01 | Why? |
| Genetic Testing | 1 | 2000 | 395 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Immunohistochemistry | 1 | 2004 | 2275 | 0.01 | Why? |
| RNA, Viral | 1 | 2004 | 32276 | 0.01 | Why? |
| Chlamydophila pneumoniae | 1 | 1996 | 98 | 0.01 | Why? |
| Leukemia, Prolymphocytic | 1 | 1995 | 10 | 0.01 | Why? |
| Berlin | 1 | 1996 | 283 | 0.01 | Why? |
| Cell Transformation, Neoplastic | 1 | 1987 | 191 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| DNA, Fungal | 1 | 1995 | 95 | 0.01 | Why? |
| Antigens, Neoplasm | 1 | 1987 | 230 | 0.01 | Why? |
| Patient Readmission | 1 | 1994 | 1543 | 0.01 | Why? |
| Lung | 1 | 2004 | 31049 | 0.01 | Why? |
| Epithelium | 1 | 1987 | 330 | 0.01 | Why? |
| Coronavirus | 1 | 2004 | 18339 | 0.01 | Why? |
| Endothelium | 1 | 1998 | 460 | 0.01 | Why? |
| Disease Progression | 1 | 2003 | 13580 | 0.01 | Why? |
| Sweat Glands | 1 | 1963 | 16 | 0.01 | Why? |
| Angiomatosis | 1 | 1963 | 12 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 1998 | 9537 | 0.01 | Why? |
| Neoplasms, Glandular and Epithelial | 1 | 1963 | 39 | 0.01 | Why? |
| Japan | 1 | 1996 | 6653 | 0.01 | Why? |
| United States | 2 | 2003 | 46150 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.01 | Why? |
| Binding Sites | 1 | 1995 | 6201 | 0.01 | Why? |
| Antibody Specificity | 1 | 1987 | 1328 | 0.01 | Why? |
| Acute Disease | 1 | 1995 | 6029 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Infection Control | 1 | 2021 | 23131 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Nitric Oxide | 1 | 1998 | 769 | 0.01 | Why? |
| Bacterial Infections | 1 | 1994 | 2229 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 1986 | 7868 | 0.01 | Why? |
| RNA, Messenger | 1 | 1995 | 5131 | 0.01 | Why? |
| Alleles | 1 | 1996 | 1557 | 0.01 | Why? |
| Critical Care | 1 | 2004 | 14081 | 0.01 | Why? |
| Psychiatric Status Rating Scales | 1 | 1996 | 1340 | 0.01 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1995 | 526 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2004 | 22116 | 0.01 | Why? |
| Antibodies, Viral | 1 | 1991 | 51949 | 0.01 | Why? |
| Epidemiologic Methods | 1 | 1991 | 392 | 0.01 | Why? |
| Genetic Variation | 1 | 2001 | 3919 | 0.00 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 1995 | 2309 | 0.00 | Why? |
| Education | 1 | 1991 | 434 | 0.00 | Why? |
| Hypersensitivity, Immediate | 1 | 1986 | 134 | 0.00 | Why? |
| Drug Therapy, Combination | 1 | 1996 | 7268 | 0.00 | Why? |
| B-Lymphocytes | 1 | 1987 | 4418 | 0.00 | Why? |
| Data Collection | 1 | 1991 | 1769 | 0.00 | Why? |
| Registries | 1 | 2001 | 12327 | 0.00 | Why? |
| Sensitivity and Specificity | 1 | 2001 | 22971 | 0.00 | Why? |
| T-Lymphocytes | 1 | 1987 | 6670 | 0.00 | Why? |
| Antibodies, Monoclonal | 1 | 1987 | 8041 | 0.00 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.00 | Why? |
| Brain | 1 | 1991 | 5133 | 0.00 | Why? |
| Neoplasms | 1 | 1963 | 17251 | 0.00 | Why? |